AXSM NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Axsome Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 241.0 USD
4.8% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 20.3% above the Trend Line and sits at 88.3% of its 52-week range. The latest completed week returned 4.8%, after a -0.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. Options positioning is bearish with 44/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 63 out of 100
Latest Close 241.0 USD 24 Jul 2026
1W Return 4.8% latest completed week
4W Return -0.3% short-term follow-through
12W Return 16.7% quarterly tape
Trend Breadth 84.6% 44 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 44-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 11 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.8% Latest completed week; four-week move -0.3%. Indicator stack 92/51 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bearish 44/100 conviction; expected move 10.3%. News sentiment 57/100 65 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 20.3% above the Trend Line and sits at 88.3% of its 52-week range. The latest completed week returned 4.8%, after a -0.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9212-week average 0.80

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.92Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1111 reversal markers

No recent accumulation markers. 11 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -0.3% over four weeks, 16.7% over 12 weeks, and 139.0% over one year. The current trend has remained active for 44 consecutive weeks.

Performance by holding period

1W4.8%
4W-0.3%
12W16.7%
26W29.6%
52W139.0%
Active trend streak44 weeks
Active weeks in one year44
Trend breadth84.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.36Latest activity-pressure read.
Pressure change-69.9%Four-week change in activity pressure.
Leadership31.66Latest relative-leadership reading.
RS change-5.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength49/100Blend of value, momentum, and quality. Underlying universe rank 52; rank 1 is best.
Value11/100Relative valuation strength. Underlying universe rank 90; rank 1 is best.
Quality75/100Profitability and accounting quality. Underlying universe rank 26; rank 1 is best.
Momentum97/100Medium-term price momentum. Underlying universe rank 4; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
17.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-0.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
92.6%
Gross profit retained from each unit of revenue.
Operating margin
-25.6%
Operating profit retained from revenue.
Free-cash-flow margin
-9.9%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
63.9%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.4%
Net share repurchases relative to market value.
Shareholder yield
-0.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

AXSM shows bearish options pressure with a 44/100 conviction score, put-call volume ratio of 5.44, expected move of 10.3%, and Sharemaestro trend signal active.

Conviction44/100
Expected move10.3%
Put/call volume5.44
Pressure-67
Speculation5
Volatility76
Trend agreement29
Open options detail
Insider activity7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 65 relevant articles.

20 positive · 42 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
Options expected move10.3%Nearest-chain priced movement where available.
52-week drawdown-7.4%Distance below the 52-week high.
13-week volatility4.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+11.1%Week of 1 May.
Worst week-10.8%Week of 27 Feb.
Latest week+4.8%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains4
Flat weeks0
Modest losses12
Sharp losses2
Recent vol4.7%13-week weekly-return volatility.
Base vol4.6%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew4.4% / -2.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape65/100

Trend, activity pressure, participation, and risk combine to a 65/100 tape read.

 Indicator analysis82/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.92; 11 reversal markers Factors56/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 75; Small Cap Core rank 92 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options36/100

AXSM shows bearish options pressure with a 44/100 conviction score, put-call volume ratio of 5.44, expected move of 10.3%, and Sharemaestro trend signal active.

Bearish · Put-side pressure · Expected move 10.3% Sentiment57/100

Weighted news tone is neutral across 65 relevant articles.

SummitTX Capital L.P. Makes New $2.59 Million Investment in Axsome Therapeutics, Inc. $AXSM Insiders7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.

 Research flow4 items

1 recent research articles and 3 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 2026241.0 USD4.8%200.4 USD115.7 USD0.3631.663.4MOn
17 Jul 2026230.0 USD-1.6%197.4 USD114.6 USD0.6625.203.7MOn
10 Jul 2026233.8 USD-4.3%194.8 USD113.6 USD0.9123.154.1MOn
3 Jul 2026244.3 USD1.1%192.0 USD112.6 USD1.1332.234.4MOn
26 Jun 2026241.7 USD-3.5%188.8 USD111.5 USD1.1933.4412.0MOn
19 Jun 2026250.5 USD-1.8%185.8 USD110.4 USD1.1333.622.6MOn
12 Jun 2026255.2 USD9.8%182.4 USD109.4 USD1.1541.333.4MOn
5 Jun 2026232.3 USD-0.9%178.6 USD108.3 USD1.0833.233.6MOn
29 May 2026234.5 USD-0.6%175.4 USD107.3 USD1.0629.602.7MOn
22 May 2026236.0 USD3.6%172.1 USD106.2 USD1.0235.412.9MOn
15 May 2026227.7 USD4.8%168.6 USD105.2 USD0.6933.553.3MOn
8 May 2026217.4 USD5.3%165.2 USD104.2 USD0.4228.255.6MOn
1 May 2026206.5 USD11.1%162.1 USD103.3 USD-0.0129.436.8MOn
24 Apr 2026186.0 USD-1.6%159.2 USD102.5 USD-0.4119.072.8MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.